[ad_1]
Source: Washington – AFP
On Thursday, the US Drug Agency issued a full license to use remdesivir to treat people with Covid-19 in hospitals, after granting conditional authorization for its use in May, according to Gilad, which makes the drug.
“Gilad” announced that it had received a license to use the drug, which is sold under the name “Viclor”, and explained that remdesivir is the only special treatment for Covid-19 that has so far received a full license, following a route stricter and final audit.
Packages of the drug in the laboratory of the company “Gilead”.
Other properties were licensed months ago, but only for emergency use. With the end of the health emergency, these licenses, which were granted based on incomplete databases, could be revoked.
Since spring, Europe and other countries have allowed the temporary use of remdesivir. Following the recent announcement, Gilead shares were up 4% on the New York Stock Exchange.
Remdesivir refills
Remdesivir is among the first drugs that have shown relative effectiveness during rigorous trials in reducing the number of days required for hospitalization for people with Covid-19.
The drug can be administered to adults and children over twelve years of age and weighing 40 kg, provided they are in hospitals or in a similar environment. An emergency license to use the drug was also granted to children under 12 years of age weighing more than 3.5 kg.
US President Donald Trump was dosed with the drug for five days when he contracted Covid-19 in early October.
[ad_2]
